TB-500 (Thymosin Beta-4):
Tissue Repair & Recovery Research
Thymosin Beta-4 (TB-500) is a naturally occurring 43-amino acid peptide and one of the most abundant intracellular peptides in mammalian cells. This guide covers its research history, proposed mechanisms, and key preclinical findings in tissue repair models.
What Is TB-500?
TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a ubiquitous 43-amino acid peptide first isolated from thymic tissue. It is one of the most abundant peptides in mammalian cells and plays a central role in G-actin sequestration — binding free actin monomers to regulate cytoskeletal dynamics. Its LKKTET motif (residues 17–23) is considered the pharmacologically active domain and has been the subject of independent research as a truncated fragment.
TB-500 has been investigated across a broad range of preclinical models including wound healing, cardiac injury, corneal repair, and neurological recovery. Lumen Peppers provides research-grade TB-500 individually and as part of the TB-500 + BPC-157 blend for combinatorial research protocols.
Key Research Findings
TB-500 has demonstrated consistent effects across multiple tissue repair and recovery models in peer-reviewed preclinical research.
Wound Healing Acceleration
Rodent excisional wound models show TB-500 significantly accelerates dermal repair through keratinocyte migration stimulation and fibroblast chemotaxis — effects attributed primarily to actin-mediated cytoskeletal remodeling at wound margins.
Cardiac Repair Research
Myocardial infarction models demonstrate TB-500 promotes cardiomyocyte survival, reduces infarct size, and stimulates progenitor cell migration to the injury site. Akt pathway activation and VEGF upregulation are proposed mechanisms.
Angiogenesis Promotion
TB-500 consistently promotes formation of new microvasculature in ischemic tissue models. VEGF receptor upregulation and endothelial cell migration via actin polymerization modulation are implicated in these findings.
Corneal Repair Studies
Topical and systemic TB-500 application in corneal injury models shows significantly accelerated epithelial healing. The peptide appears to promote limbal stem cell migration and differentiation in these studies.
Neurological Recovery
CNS injury models including stroke and traumatic brain injury show TB-500 reduces lesion volume, promotes neurogenesis in the subventricular zone, and improves functional recovery in behavioral assays.
Anti-Inflammatory Activity
Multiple models demonstrate TB-500 suppresses pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) and modulates macrophage polarization toward an M2/reparative phenotype in wound and inflammatory models.
Proposed Mechanisms of Action
TB-500's primary identified function is binding G-actin (monomeric actin) with high affinity, preventing polymerization and maintaining a dynamic actin pool. This regulates cell migration, morphology, and mechanosensing in virtually all cell types.
The hexapeptide LKKTET (residues 17-23) is the actin-binding domain and retains significant biological activity as an isolated fragment. Studies show this motif is sufficient to promote wound healing and cell migration in multiple models.
Cardiac and vascular studies indicate TB-500 activates the PI3K/Akt pro-survival pathway, promoting cardiomyocyte protection from apoptosis and stimulating endothelial progenitor cell recruitment to ischemic tissue.
TB-500 increases VEGF expression in multiple tissue types, driving angiogenesis. This is observed in wound healing, cardiac ischemia, and corneal repair models — often synergistically with co-administered compounds like BPC-157.
Anti-inflammatory effects are partially attributed to TB-500's inhibition of NF-κB nuclear translocation, reducing transcription of pro-inflammatory cytokines and shifting macrophage populations toward reparative phenotypes.
Active Research Applications
Dermal Wound Models
Full-thickness excisional wound models, burn injury studies, and diabetic wound healing research in rodents using subcutaneous and topical TB-500 administration protocols.
Cardiac Regeneration
Post-MI models investigating progenitor cell recruitment, cardiomyocyte protection, and scar tissue reduction with systemic TB-500 administration.
Musculoskeletal Repair
Tendon, ligament, and muscle injury models — often in combination with BPC-157 — investigating accelerated structural tissue recovery.
Ocular Surface Research
Corneal epithelial defect models, dry eye syndrome studies, and limbal stem cell migration research using topical TB-500 preparations.
Neurological Models
Stroke, TBI, and spinal cord injury models examining TB-500's effects on neurogenesis, axonal sprouting, and functional behavioral recovery.
In Vitro Migration Assays
Scratch assay and Boyden chamber studies in fibroblast, keratinocyte, and endothelial cell lines to characterize the direct migratory effects of TB-500 and its active fragments.
Protocol Notes for Researchers
TB-500 + BPC-157 Synergy
TB-500 and BPC-157 are frequently co-administered in preclinical research due to their complementary mechanisms: TB-500 drives actin-mediated cell migration while BPC-157 activates FAK-paxillin and VEGFR2 pathways. Lumen Peppers offers a pre-blended research formulation for convenience.
TB-500 — Research Grade ≥99% Purity
Research-grade purity ≥99% · Third-party HPLC verified · Ships from the U.S.
All products sold by Lumen Peppers are intended exclusively for in vitro laboratory research and investigative purposes. These compounds are not approved by the FDA for human or veterinary use. They are not drugs, supplements, or medications. Lumen Peppers makes no therapeutic claims. Researchers are solely responsible for ensuring compliance with all applicable laws and regulations in their jurisdiction.